Patient leaflet - Zomarist
1. What Zomarist is and what it is used for
The active substances of Zomarist, vildagliptin and metformin, belong to a group of medicines called “oral antidiabetics”.
Zomarist is used to treat adult patients with type 2 diabetes. This type of diabetes is also known as non-insulin-dependent diabetes mellitus. Zomarist is used when diabetes cannot be controlled by diet and exercise alone and/or with other medicines used to treat diabetes (insulin or sulphonylureas).
Type 2 diabetes develops if the body does not make enough insulin or if the insulin that the body makes does not work as well as it should. It can also develop if the body produces too much glucagon.
Both insulin and glucagon are made in the pancreas. Insulin helps to lower the level of sugar in the blood, especially after meals. Glucagon triggers the liver to make sugar, causing the blood sugar level to rise.
How Zomarist works
Both active substances, vildagliptin and metformin, help to control the level of sugar in the blood. The substance vildagliptin works by making the pancreas produce more insulin and less glucagon. The substance metformin works by helping the body to make better use of insulin. This medicine has been shown to reduce blood sugar, which may help to prevent complications from your diabetes.
2. What you need to know before you take Zomarist
Do not take Zomarist
-
– if you are allergic to vildagliptin, metformin or any of the other ingredients of this medicine
(listed in section 6). If you think you may be allergic to any of these, talk to your doctor before taking Zomarist.
-
– if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood
glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see “Risk of lactic acidosis” below) or ketoacidosis. Ketoacidosis is a condition in which substances called ketone bodies accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity smell.
-
– if you have recently had a heart attack or if you have heart failure or serious problems with your
blood circulation or difficulties in breathing which could be a sign of heart problems.
-
– if you have severely reduced kidney function.
-
– if you have a severe infection or are seriously dehydrated (have lost a lot of water from your
body).
-
– if you are going to have a contrast x-ray (a specific type of x-ray involving an injectable dye).
Please also see information about this in section “Warnings and precautions”.
-
– if you have liver problems.
-
– if you drink alcohol excessively (whether every day or only from time to time).
-
– if you are breast-feeding (see also “Pregnancy and breast-feeding”).
Warnings and precautions
Risk of lactic acidosis
Zomarist may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).
If any of the above apply to you, talk to your doctor for further instructions.
Stop taking Zomarist for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.
Stop taking Zomarist and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis , as this condition may lead to coma.
Symptoms of lactic acidosis include:
-
– vomiting
-
– stomach ache (abdominal pain)
-
– muscle cramps
-
– a general feeling of not being well with severe tiredness
-
– difficulty in breathing
-
– reduced body temperature and heartbeat
Lactic acidosis is a medical emergency and must be treated in a hospital.
Zomarist is not a substitute for insulin. Therefore, you should not receive Zomarist for the treatment of type 1 diabetes.
Talk to your doctor, pharmacist or nurse before taking Zomarist if you have or have had a disease of the pancreas.
Talk to your doctor, pharmacist or nurse before taking Zomarist if you are taking an anti-diabetic medicine known as a sulphonylurea. Your doctor may want to reduce your dose of the sulphonylurea when you take it together with Zomarist in order to avoid low blood glucose (hypoglycaemia).
If you have previously taken vildagliptin but had to stop taking it because of liver disease, you should not take this medicine.
Diabetic skin lesions are a common complication of diabetes. You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse. You are also advised to pay particular attention to new onset of blisters or ulcers while taking Zomarist. Should these occur, you should promptly consult your doctor.
If you need to have major surgery you must stop taking Zomarist during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Zomarist.
A test to determine your liver function will be performed before the start of Zomarist treatment, at three-month intervals for the first year and periodically thereafter. This is so that signs of increased liver enzymes can be detected as early as possible.
During treatment with Zomarist, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or have worsening renal function.
Your doctor will test your blood and urine for sugar regularly.
Children and adolescents
The use of Zomarist in children and adolescents up to 18 years of age is not recommended.
Other medicines and Zomarist
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Zomarist before or at the time of the injection. Your doctor will decide when you must stop and when to restart your treatment with Zomarist.
Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests or your doctor may need to adjust the dosage of Zomarist. It is especially important to mention the following: – glucocorticoids generally used to treat inflammation
-
– beta-2 agonists generally used to treat respiratory disorders
-
– other medicines used to treat diabetes
-
– medicines which increase urine production (diuretics)
-
– medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as
ibuprofen and celecoxib)
-
– certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II
receptor antagonists)
-
– certain medicines affecting the thyroid
-
– certain medicines affecting the nervous system
-
– certain medicines used to treat angina (e.g. ranolazine)
-
– certain medicines used to treat HIV infection (e.g. dolutegravir)
-
– certain medicines used to treat a specific type of thyroid cancer (medullary thyroid cancer) (e.g.
vandetanib)
-
– certain medicines used to treat heartburn and peptic ulcers (e.g cimetidine)
Zomarist with alcohol
Avoid excessive alcohol intake while taking Zomarist since this may increase the risk of lactic acidosis (please see section “Warnings and precautions”).
Pregnancy and breast-feeding
-
– If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor
for advice before taking this medicine. Your doctor will discuss with you the potential risk of taking Zomarist during pregnancy.
-
– Do not use Zomarist if you are pregnant or breast-feeding (see also “Do not take Zomarist”).
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
If you feel dizzy while taking Zomarist, do not drive or use any tools or machines.
3. How to take Zomarist
The amount of Zomarist that people have to take varies depending on their condition. Your doctor will tell you exactly the dose of Zomarist to take.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one film-coated tablet of either 50 mg/850 mg or 50 mg/1000 mg taken twice a day
If you have reduced kidney function, your doctor may prescribe a lower dose. Also if you are taking an anti-diabetic medicine known as a sulphonylurea your doctor may prescribe a lower dose.
Your doctor may prescribe this medicine alone or with certain other medicines that lower the level of sugar in your blood.
When and how to take Zomarist
-
– Swallow the tablets whole with a glass of water,
-
– Take one tablet in the morning and the other in the evening with or just after food. Taking the
tablet just after food will lower the risk of an upset stomach.
Continue to follow any advice about diet that your doctor has given you. In particular, if you are following a diabetic weight control diet, continue with this while you are taking Zomarist.
If you take more Zomarist than you should
If you take too many Zomarist tablets, or if someone else takes your tablets, talk to a doctor or pharmacist immediately. Medical attention may be necessary. If you have to go to a doctor or hospital, take the pack and this leaflet with you.
If you forget to take Zomarist
If you forget to take a tablet, take it with your next meal unless you are due to take one then anyway.
Do not take a double dose (two tablets at once) to make up for a forgotten tablet.
If you stop taking Zomarist
Continue to take this medicine as long as your doctor prescribes it so that it can continue to control your blood sugar. Do not stop taking Zomarist unless your doctor tells you to. If you have any questions about how long to take this medicine, talk to your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You should stop taking Zomarist and see your doctor immediately if you experience the following side effects:
- Lactic acidosis (very rare: may affect up to 1 user in 10,000):
Zomarist may cause a very rare, but very serious side effect called lactic acidosis (see section “Warnings and precautions”). If this happens you must stop taking Zomarist and contact a doctor or the nearest hospital immediately , as lactic acidosis may lead to coma.
- Angioedema (rare: may affect up to 1 in 1,000 people): Symptoms include swollen face, tongue
or throat, difficulty swallowing, difficulty breathing, sudden onset of rash or hives, which may indicate a reaction called “angioedema”.
- Liver disease (hepatitis) (rare): Symptoms include yellow skin and eyes, nausea, loss of appetite
or dark-coloured urine, which may indicate liver disease (hepatitis).
- Inflammation of the pancreas (pancreatitis) (frequency not known): Symptoms include severe
and persistent pain in the abdomen (stomach area), which might reach through to your back, as well as nausea and vomiting.
Other side effects
Some patients have experienced the following side effects while taking Zomarist:
- Very common (may affect more than 1 in 10 people): nausea, vomiting, diarrhoea, pain in and
around the stomach (abdominal pain), loss of appetite.
- Common (may affect up to 1 in 10 people): dizziness, headache, trembling that cannot be
controlled, metallic taste, low blood glucose.
- Uncommon (may affect up to 1 in 100 people): joint pain, tiredness, constipation, swollen
hands, ankle or feet (oedema).
- Very rare (may affect up to 1 in 10,000 people): sore throat, runny nose, fever; signs of a high
level of lactic acid in the blood (known as lactic acidosis) such as drowsiness or dizziness, severe nausea or vomiting, abdominal pain, irregular heart beat or deep, rapid breathing; redness of the skin, itching; decreased vitamin B12 levels (paleness, tiredness, mental symptoms such as confusion or memory disturbances).
Some patients have experienced the following side effects while taking Zomarist and a sulphonylurea:
- Common: dizziness, tremor, weakness, low blood glucose, excessive sweating.
Some patients have had the following side effects while taking Zomarist and insulin:
- Common: headache, chills, nausea (feeling sick), low blood glucose, heartburn.
- Uncommon: diarrhoea, flatulence.
Since this product has been marketed, the following side effects have also been reported:
- Frequency not known (cannot be estimated from the available data): itchy rash, inflammation of
the pancreas, localised peeling of skin or blisters, muscle pain.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Zomarist
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after “EXP”. The expiry date refers to the last day of that month.
Do not store above 30°C.
Store in the original package (blister) in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Zomarist contains
-
– The active substances are vildagliptin and metformin hydrochloride.
-
– Each Zomarist 50 mg/850 mg film-coated tablet contains 50 mg vildagliptin and 850 mg
metformin hydrochloride (corresponding to 660 mg of metformin).
-
– Each Zomarist 50 mg/1000 mg film-coated tablet contains 50 mg vildagliptin and 1000 mg
metformin hydrochloride (corresponding to 780 mg of metformin).
-
– The other ingredients are: Hydroxypropylcellulose, magnesium stearate, hypromellose, titanium
What Zomarist looks like and contents of the pack
Zomarist 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Zomarist 50 mg/1000 mg film-coated tablets are dark yellow, oval tablets with “NVR” on one side and “FLO” on the other.
Zomarist is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multipacks containing 120 (2×60), 180 (3×60) or 360 (6×60) film-coated tablets. Not all pack sizes and tablet strengths may be available in your country.
Marketing Authorisation Holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Manufacturer
Lek d.d, PE PROIZVODNJA LENDAVA
Trimlini 2D
Lendava, 9220
Slovenia
Novartis Pharma GmbH
RoonstraBe 25
D-90429 Nuremberg
Germany
For any information about this medicine, please
Authorisation Holder:
België/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11
Efc^rapufl
Novartis Bulgaria EOOD
Ten.: +359 2 489 98 28
Česká republika
Novartis s.r.o.
Tel: +420 225 775 111
Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00
Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0
Eesti
SIA Novartis Baltics Eesti filiaal
Tel: +372 66 30 810
EÀÀàôa
Novartis (Hellas) A.E.B.E.
Tql: +30 210 281 17 12
n
WIN MEDICA OAPMAKEYTIKH A.E.
Tql: +30 210 74 88 821
España
Esteve Pharmaceuticals, S.A.
Tel: +34 93 446 60 00
France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00
Hrvatska
Novartis Hrvatska d.o.o.
Tel. +385 1 6274 220
Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55
Ísland
Vistor hf.
Sími: +354 535 7000
contact the local representative of the Marketing
Lietuva
SIA Novartis Baltics Lietuvos filialas
Tel: +370 5 269 16 50
Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11
Magyarorszag
Novartis Hungaria Kft.
Tel.: +36 1 457 65 00
Malta
Novartis Pharma Services Inc.
Tel: +356 2122 2872
Nederland
Novartis Pharma B.V.
Tel: +31 88 04 52 111
Norge
Novartis Norge AS
Tlf: +47 23 05 20 00
Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570
Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888
Portugal
Bialport-Produtos Farmacêuticos, S.A.
Tel: +351 22 986 61 00
România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01
Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50
Slovenská republika
Novartis Slovakia s.r.o.
Tel: +421 2 5542 5439
Italia
Novartis Farma S.p.A.
Tel: +39 02 96 54 1
Suomi/Finland
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200
Kûnpoç
Novartis Pharma Services Inc.
Tql: +357 22 690 690
Sverige
Novartis Sverige AB
Tel: +46 8 732 32 00
Latvija
SIA Novartis Baltics
Tel: +371 67 887 070
United Kingdom (Northern Ireland)
Novartis Ireland Limited
Tel: +44 1276 698370
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website:
51